The effect of androgen deprivation therapy on body composition in men with prostate cancer: systematic review and meta-analysis
- PMID: 20091248
- DOI: 10.1007/s11764-009-0114-1
The effect of androgen deprivation therapy on body composition in men with prostate cancer: systematic review and meta-analysis
Abstract
Introduction: The use of androgen deprivation therapy (ADT) in the treatment of prostate cancer is associated with changes in body composition including increased fat and decreased lean mass. Limited information exists regarding the rate and extent of these changes. This systematic review was conducted to determine the effects of ADT on body composition in prostate cancer patients.
Methods: Literature searches were conducted on MEDLINE, EMBASE and Web of Science for studies until January 2009. Only longitudinal studies that examined ADT and body composition in prostate cancer patients were included. Data were extracted on body weight, BMI, percentage of fat mass and lean body mass.
Results: Sixteen studies (14 cohorts and 2 RCTs) met the inclusion criteria. Pooled data, calculated according to a random effects model, showed that ADT increased % body fat by on average 7.7% (95% CI 4.3, 11.2, from seven studies, P < 0.0001) and decreased % lean body mass by on average -2.8% (95% CI -3.6, -2.0, from six studies, P < 0.0001) but for both there was marked heterogeneity between studies (I2 = 99% I2 = 73%, respectively). Similarly, body weight (2.1%, P < 0.0001 from nine studies) and BMI (2.2%, P < 0.0001, from eight studies) increased significantly. More extensive changes were seen with longer duration of treatment.
Conclusions: Substantial increases in fat and declines in lean mass were observed in prostate cancer patients treated with ADT. Lifestyle changes or suitable interventions to minimize the effect of ADT on body composition need to be investigated.
Implications for cancer survivors: Prostate cancer survivors should be made aware of the side effect of treatment on body composition and further work is required to determine what interventions can minimize the impact of ADT on body composition and therefore what evidence based advice they should be provided with. In general, though recommendation of a healthy diet and moderate exercise is reasonable.
Similar articles
-
Dietary interventions to improve body composition in men treated with androgen deprivation therapy for prostate cancer: a solution for the growing problem?Prostate Cancer Prostatic Dis. 2022 Feb;25(2):149-158. doi: 10.1038/s41391-021-00411-7. Epub 2021 Jun 30. Prostate Cancer Prostatic Dis. 2022. PMID: 34193946 Free PMC article.
-
Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer.Cochrane Database Syst Rev. 2006 Oct 18;2006(4):CD006019. doi: 10.1002/14651858.CD006019.pub2. Cochrane Database Syst Rev. 2006. PMID: 17054269 Free PMC article.
-
Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.Cochrane Database Syst Rev. 2002;(1):CD003506. doi: 10.1002/14651858.CD003506. Cochrane Database Syst Rev. 2002. Update in: Cochrane Database Syst Rev. 2019 Jun 11;6:CD003506. doi: 10.1002/14651858.CD003506.pub2. PMID: 11869665 Updated.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 23;5:CD011535. doi: 10.1002/14651858.CD011535.pub5. PMID: 33871055 Free PMC article. Updated.
-
Physical exercise training interventions for children and young adults during and after treatment for childhood cancer.Cochrane Database Syst Rev. 2016 Mar 31;3(3):CD008796. doi: 10.1002/14651858.CD008796.pub3. Cochrane Database Syst Rev. 2016. PMID: 27030386 Free PMC article.
Cited by
-
Incidence of the adverse effects of androgen deprivation therapy for prostate cancer: a systematic literature review.Support Care Cancer. 2020 May;28(5):2079-2093. doi: 10.1007/s00520-019-05255-5. Epub 2020 Jan 7. Support Care Cancer. 2020. PMID: 31912360
-
Achieving optimal delivery of follow-up care for prostate cancer survivors: improving patient outcomes.Patient Relat Outcome Meas. 2015 Mar 19;6:75-90. doi: 10.2147/PROM.S49588. eCollection 2015. Patient Relat Outcome Meas. 2015. PMID: 25834471 Free PMC article. Review.
-
Androgen-deprivation therapy with leuprolide increases abdominal adiposity without causing cardiac dysfunction in middle-aged male mice: effect of sildenafil.Am J Physiol Regul Integr Comp Physiol. 2023 Apr 1;324(4):R589-R600. doi: 10.1152/ajpregu.00259.2022. Epub 2023 Mar 6. Am J Physiol Regul Integr Comp Physiol. 2023. PMID: 36878484 Free PMC article.
-
Dysfunctional Lipid Metabolism-The Basis for How Genetic Abnormalities Express the Phenotype of Aggressive Prostate Cancer.Cancers (Basel). 2023 Jan 4;15(2):341. doi: 10.3390/cancers15020341. Cancers (Basel). 2023. PMID: 36672291 Free PMC article. Review.
-
Heterogeneity in regional changes in body composition induced by androgen deprivation therapy in prostate cancer patients: potential impact on bone health-the BLADE study.J Endocrinol Invest. 2024 Feb;47(2):335-343. doi: 10.1007/s40618-023-02150-z. Epub 2023 Jul 17. J Endocrinol Invest. 2024. PMID: 37458931 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous